Efficacy and Safety of Systemic Prophylactic Antibacterials in Mechanically Ventilated Patients: Systematic Review
Qiuying Yu1,2, Ziyang Wu1,3, Qinggang Ge1
1Department of Pharmacy, Peking University Third Hospital, Beijing, China.
Objectives:
Previous studies have shown that selective decontamination of the digestive tract can reduce the incidence and mortality of ventilator-associated pneumonia (VAP) in mechanically ventilated patients. However, the prophylactic role of IV antibacterials, one of its essential components, remains unclear. Therefore, this study aims to evaluate the efficacy and safety of systemic prophylactic use of antibacterials in mechanically ventilated patients.
Data Sources:
We systematically searched PubMed, Embase, and The Cochrane Library from inception to November 30, 2025.
Study Selection:
Randomized controlled trials (RCTs) evaluating prophylactic use of systemic antibacterials in mechanically ventilated patients in the ICUs were included.
Data Extraction:
Two researchers independently conducted literature screening, data extraction, and quality assessment. Meta-analysis was performed using RevMan 5.4, and the quality of the evidence was evaluated using the recommended Grading of Recommendations, Assessment, Development, and Evaluation method.
Data Synthesis:
Eleven RCTs with 5562 patients were included. Meta-analysis results showed that the systemic prophylactic use of antibacterials probably reduces the incidence of VAP (relative risk [RR], 0.65; 95% CI, 0.55-0.77; moderate certainty) and the incidence of early VAP (RR, 0.52; 95% CI, 0.41-0.66; moderate certainty), but probably does not reduce in-hospital mortality (RR, 0.85; 95% CI, 0.68-1.06; moderate certainty) or duration of mechanical ventilation (mean difference [MD], -0.32; 95% CI, -0.79 to 0.16; moderate certainty), and may not reduce length of hospital stay (MD, -1.56; 95% CI, -5.15 to 2.02; low certainty). Subgroup analyses suggested that systemic prophylactic antibacterials probably reduces VAP in brain injury patients. No increased risk of drug resistance and adverse events was observed.
Conclusions:
The systemic prophylactic antibacterials probably reduces early VAP and overall VAP incidence in mechanically ventilated patients, but probably does not reduce in-hospital mortality. Subgroup analyses suggested potential benefits in brain injury patients. Given incomplete safety reporting, future research should include comprehensive resistance surveillance and cost-effectiveness analyses.
Related Concept Videos
01:25Mechanism of Antibiotic Resistance in MRSA
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:25Clinical Significance of Antibiotic Resistance
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Antimicrobial Effectiveness
01:23Mechanical Ventilation II: Invasive Ventilation
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...